Ondansetron treatment in patients with Tourette's syndrome.

Ondansetron, a selective 5-HT3 antagonist, may lower mesolimbic dopaminergic hyperactivity. The present open-label pilot study evaluated the effect of ondansetron in Tourette's syndrome. Six Tourette's syndrome men aged 14-48 years resistant to haloperidol participated in the study. Assessments included the Yale Global Tic Severity Scale (YGTSS), Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), and Tourette's syndrome-Clinical Global Impression (TS-CGI) scale. The maximal ondansetron dosage (8-16 mg per day) was given for 3 weeks. Ondansetron treatment was associated with a significant decrease in the severity of tics. Two patients showed a definite response (score improvement of 40% or more), and two showed a probable response (> 25%). Two patients did not improve. Side-effects were transient and included abdominal pain (n = 5) and constipation (n = 2). Ondansetron may possess anti-tic effects in some Tourette's syndrome patients.
AuthorsP Toren, N Laor, D J Cohen, L Wolmer, A Weizman
JournalInternational clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 14 Issue 6 Pg. 373-6 (Nov 1999) ISSN: 0268-1315 [Print] ENGLAND
PMID10565805 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Serotonin Antagonists
  • Ondansetron
  • Adolescent
  • Adult
  • Female
  • Humans
  • Male
  • Middle Aged
  • Obsessive-Compulsive Disorder (complications, drug therapy, psychology)
  • Ondansetron (adverse effects, therapeutic use)
  • Pilot Projects
  • Psychiatric Status Rating Scales
  • Serotonin Antagonists (adverse effects, therapeutic use)
  • Tourette Syndrome (complications, drug therapy, psychology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: